Trends in use and costs of prescription medication in patients with type 1 diabetes: 9-year follow-up after kidney transplantation

Aims: Weestimated long-term trends in prescription medication utilization and costs in patients with type 1 diabetes in two different transplant cohorts (Group 1: transplantation 1986-1999,n = 180; Group 2: transplantation 2000-2008, n = 150). Methods: Data obtained from the Finnish Diabetic Nephropathy Study were linked with the Drug Prescription Register (purchases of medications 1995-2009). Generalized linear mixed models under gamma distribution were used to evaluate the medication costs. Results: The total costs of medication decreased (Group 1 from€11,290 to €8760; Group 2 from €12,800 to €9790)during the follow-up (P

[1]  P Fauchald,et al.  PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION , 1995 .

[2]  M. Sayegh,et al.  Immunosuppressive strategies in transplantation , 1999, The Lancet.

[3]  R. Wolfe,et al.  Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. , 1999, The New England journal of medicine.

[4]  Joshua Miller,et al.  A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. , 2002, Transplantation.

[5]  Harri Sintonen,et al.  Cost analysis of renal replacement therapies in Finland. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  K. Salmela,et al.  Two decades of experience with cyclosporine in renal transplantation in Helsinki. , 2004, Transplantation proceedings.

[7]  C. Alexander,et al.  End-stage renal disease-associated managed care costs among patients with and without diabetes. , 2004, Diabetes care.

[8]  Miguel Angel Gentil,et al.  Impact of the new drugs in the cost of maintenance immunosuppression of renal transplantation. Is it justified? , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  H. Isoniemi,et al.  [Selection of organ transplant drugs is increasing]. , 2004, Duodecim; laaketieteellinen aikakauskirja.

[10]  J Raftery,et al.  Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. , 2005, Health technology assessment.

[11]  Merlin C. Thomas,et al.  Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). , 2005, Diabetes care.

[12]  Ron Shapiro,et al.  Immunosuppression: evolution in practice and trends, 1993–2003 , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  W. John Boscardin,et al.  SAS® for mixed models (2nd edn). Ramon C. Littell, George A. Milliken, Walter W. Stroup, Russell D. Wolfinger and Oliver Schabenberger, SAS Institute, Cary, NC, 2006. No. of pages: xii + 814. Price: $89.95. ISBN 10: 1-59047-500-3; ISBN 13: 978-1-59047-500-3 , 2007 .

[14]  H. Meier‐Kriesche,et al.  Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[15]  D. Game,et al.  Modern renal transplantation: present challenges and future prospects , 2009, Postgraduate Medical Journal.

[16]  J. Grinyó,et al.  Mycophenolate Mofetil and Calcineurin‐Inhibitor Reduction: Recent Progress , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  W. Arns,et al.  Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach , 2010, The European Journal of Health Economics.

[18]  G. Levy,et al.  Progress in Transplantation , 2010, Therapeutic drug monitoring.

[19]  F. Luan,et al.  Transplantation in Diabetic Kidney Failure Patients: Modalities, Outcomes, and Clinical Management , 2010, Seminars in dialysis.

[20]  C. Forsblom,et al.  Cumulative cost of prescription medication in outpatients with type 1 diabetes in Finland , 2011, Diabetologia.

[21]  Ethan M Balk,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.

[22]  Klemens Budde,et al.  Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk , 2010, Transplant international : official journal of the European Society for Organ Transplantation.

[23]  A. Jardine,et al.  Prevention of cardiovascular disease in adult recipients of kidney transplants , 2011, The Lancet.

[24]  L. Awdishu,et al.  Steroids in kidney transplant patients , 2011, Seminars in Immunopathology.

[25]  Teun van Gelder,et al.  Current immunosuppressive treatment after kidney transplantation , 2011, Expert opinion on pharmacotherapy.

[26]  P. C.-M. Mao,et al.  Trends in the use of immunosuppressive agents by outpatients after renal transplantation at a medical center in southern Taiwan. , 2012, Transplantation proceedings.

[27]  S. Chadban,et al.  Mycophenolate Versus Azathioprine for Kidney Transplantation: A 15-Year Follow-Up of a Randomized Trial , 2012, Transplantation.

[28]  Cynthia F Corbett,et al.  Risks of subsequent hospitalization and death in patients with kidney disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[29]  D. Pavlović,et al.  Diabetic nephropathy: diagnosis, prevention and treatment , 2013 .